

Jeong-Won Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4441654/publications.pdf>

Version: 2024-02-01

146
papers

2,963
citations

212478

28
h-index

242451

47
g-index

148
all docs

148
docs citations

148
times ranked

5245
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival. <i>Cancer Research and Treatment</i> , 2022, 54, 245-252.	1.3	5
2	Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches. , 2022, 10, e003928.		10
3	Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2022, 165, 270-280.	0.6	5
4	Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. <i>Gynecologic Oncology</i> , 2022, , .	0.6	2
5	Clinical outcome of pulmonary lymphangitic carcinomatosis in gynecologic malignancy: A single-institution experience. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2022, 61, 333-338.	0.5	3
6	Real-world experience of pembrolizumab and lenvatinib in recurrent endometrial cancer: A multicenter study in Korea. <i>Gynecologic Oncology</i> , 2022, 165, 369-375.	0.6	6
7	Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers. <i>Cancer Research and Treatment</i> , 2022, 54, 1200-1208.	1.3	11
8	Prognostic Significance of HER3 Expression in Patients with Cervical Cancer. <i>Cancers</i> , 2022, 14, 2139.	1.7	3
9	Sensitive detection of cancer using deep learning model of cfDNA genome-wide methylation data.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18789-e18789.	0.8	0
10	Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 3850-3861.	3.2	1
11	Vulvar epithelioid sarcoma: A case report with literature review. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2021, 60, 132-135.	0.5	8
12	Comparisons of survival outcomes between bevacizumab and olaparib in <i>BRCA</i> -mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052). <i>Journal of Gynecologic Oncology</i> , 2021, 32, e90.	1.0	2
13	Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e94.	1.0	3
14	Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e72.	1.0	3
15	Minimally-Invasive Versus Abdominal Hysterectomy for Endometrial Carcinoma With Glandular or Stromal Invasion of Cervix. <i>Frontiers in Oncology</i> , 2021, 11, 670214.	1.3	2
16	Single-port access (SPA) laparoscopic myomectomy with uterine artery ligation via a retroperitoneal approach is feasible in women with large uterine leiomyoma. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2021, 60, 752-757.	0.5	1
17	Early Metabolic Response Assessed Using ¹⁸ F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 803-812.	1.3	2
18	Validation of Potential Protein Markers Predicting Chemoradioresistance in Early Cervical Cancer by Immunohistochemistry. <i>Frontiers in Oncology</i> , 2021, 11, 665595.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Establishment and preclinical application of a patient-derived xenograft model for uterine cancer. <i>Gynecologic Oncology</i> , 2021, 162, 173-181.	0.6	6
20	NIR irradiation-controlled drug release utilizing injectable hydrogels containing gold-labeled liposomes for the treatment of melanoma cancer. <i>Acta Biomaterialia</i> , 2021, 136, 508-518.	4.1	20
21	Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. <i>Cancer Science</i> , 2021, 112, 5055-5067.	1.7	6
22	The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. <i>Biomaterials</i> , 2021, 279, 121189.	5.7	27
23	Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 770103.	1.3	2
24	Machine Learning for Recurrence Prediction of Gynecologic Cancers Using Lynch Syndrome-Related Screening Markers. <i>Cancers</i> , 2021, 13, 5670.	1.7	7
25	Cytoplasmic expression of EGFR shRNA using a modified T7 autogene-based hybrid mRNA/DNA system induces long-term EGFR silencing and prolongs antitumor effects. <i>Biochemical Pharmacology</i> , 2020, 171, 113735.	2.0	6
26	CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 211-221.	0.6	15
27	Feasibility of Single-Port Access (SPA) Laparoscopy for Large Ovarian Tumor Suspected to Be Borderline Ovarian Tumor. <i>Frontiers in Oncology</i> , 2020, 10, 583515.	1.3	4
28	Chloroquine reverses chemoresistance via upregulation of p21WAF1/CIP1 and autophagy inhibition in ovarian cancer. <i>Cell Death and Disease</i> , 2020, 11, 1034.	2.7	37
29	First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092679.	1.4	9
30	Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type. <i>Journal of Clinical Medicine</i> , 2020, 9, 3471.	1.0	8
31	Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer. <i>Pharmaceutics</i> , 2020, 12, 987.	2.0	6
32	<p>Efficacy of Combination Therapy with Linalool and Doxorubicin Encapsulated by Liposomes as a Two-in-One Hybrid Carrier System for Epithelial Ovarian Carcinoma<p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 8427-8436.	3.3	7
33	Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041). <i>Cancers</i> , 2020, 12, 3188.	1.7	8
34	Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer. <i>Scientific Reports</i> , 2020, 10, 4904.	1.6	10
35	KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer. <i>Journal of Controlled Release</i> , 2020, 321, 184-197.	4.8	32
36	Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer. <i>Current Problems in Cancer</i> , 2020, 44, 100557.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 147.	1.0	14
38	Comparison of Laparoscopy and Laparotomy for Para-Aortic Lymphadenectomy in Women With Presumed Stage II High-Risk Endometrial Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 451.	1.3	4
39	Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1137.	1.0	2
40	Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R). <i>European Journal of Cancer</i> , 2020, 133, 56-65.	1.3	4
41	Long-term outcomes of single-port laparoscopic myomectomy using a modified suture technique. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 164-172.	0.6	5
42	Combination of a pulmonary recruitment maneuver and intraperitoneal bupivacaine for the reduction of postoperative shoulder pain in gynecologic laparoscopy: a randomized, controlled trial. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 187-194.	0.6	6
43	Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer. <i>Scientific Reports</i> , 2019, 9, 15394.	1.6	27
44	Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff?. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e11.	1.0	8
45	Influence of time lapse after cancer diagnosis on the association between unmet needs and quality of life in family caregivers of Korean cancer patients. <i>European Journal of Cancer Care</i> , 2019, 28, e13089.	0.7	8
46	Comparison of urine, self-collected vaginal swab, and cervical swab samples for detecting human papillomavirus (HPV) with Roche Cobas HPV, Anyplex II HPV, and RealTime HR-S HPV assay. <i>Journal of Virological Methods</i> , 2019, 269, 77-82.	1.0	25
47	Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708). <i>BMC Cancer</i> , 2019, 19, 341.	1.1	12
48	Prognostic factors for recurrence and survival in uterine leiomyosarcoma: Korean single center experience with 50 cases. <i>Obstetrics and Gynecology Science</i> , 2019, 62, 103.	0.6	5
49	Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e65.	1.0	38
50	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. <i>Genome Biology</i> , 2019, 20, 253.	3.8	16
51	Functional loss in daily activity in ovarian cancer patients undergoing chemotherapy. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1063-1069.	0.8	8
52	Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041). <i>Gynecologic Oncology</i> , 2019, 152, 61-67.	0.6	26
53	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3104-3104.	0.8	2
54	Comparison between laparoendoscopic single-site and conventional laparoscopic surgery in mature cystic teratoma of the ovary. <i>Gynecology and Minimally Invasive Therapy</i> , 2019, 8, 155.	0.2	10

#	ARTICLE	IF	CITATIONS
55	Prevalence and oncologic outcomes of <i>BRCA1/2</i> mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea. <i>Obstetrics and Gynecology Science</i> , 2019, 62, 411.	0.6	7
56	Preoperative [18F]FDG PET/CT tumour heterogeneity index in patients with uterine leiomyosarcoma: a multicentre retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1309-1316.	3.3	19
57	Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e56.	1.0	20
58	Disparities in Cervical Cancer Screening Among Women With Disabilities: A National Database Study in South Korea. <i>Journal of Clinical Oncology</i> , 2018, 36, 2778-2786.	0.8	50
59	Genomic Network-Based Analysis Reveals Pancreatic Adenocarcinoma Up-Regulating Factor-Related Prognostic Markers in Cervical Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 465.	1.3	6
60	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. <i>Nature Genetics</i> , 2018, 50, 1399-1411.	9.4	145
61	Clinical characteristics and outcomes of placental site trophoblastic tumor: experience of single institution in Korea. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 319.	0.6	8
62	Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 352.	0.6	4
63	The role of appendectomy in patients with mucinous borderline ovarian tumors. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 229, 112-116.	0.5	10
64	Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 524.	0.6	9
65	Sigmoid colon perforation after postoperative hypofractionated intensity-modulated radiation therapy in a cervical cancer patient. <i>Cancer Reports</i> , 2018, 1, e1129.	0.6	1
66	Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2018, 143, 325-332.	1.0	11
67	CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2018, 78, 6247-6256.	0.4	104
68	Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer. <i>Drug Delivery</i> , 2018, 25, 1394-1402.	2.5	57
69	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14501-e14501.	0.8	1
70	Can simple trachelectomy or conization show comparable survival rate compared with radical trachelectomy in IA1 cervical cancer patients with lymphovascular space invasion who wish to save fertility? A systematic review and guideline recommendation. <i>PLoS ONE</i> , 2018, 13, e0189847.	1.1	11
71	Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 461-473.	1.3	3
72	Preservation of the endometrial enhancement after magnetic resonance imaging-guided high-intensity focused ultrasound ablation of submucosal uterine fibroids. <i>European Radiology</i> , 2017, 27, 3956-3965.	2.3	16

#	ARTICLE	IF	CITATIONS
73	Minimally invasive compared with open surgery in patients with borderline ovarian tumors. <i>Gynecologic Oncology</i> , 2017, 145, 508-512.	0.6	21
74	Effective thermal destruction of residual tubal epithelium using an advanced sealing device in opportunistic salpingectomy: A randomized trial. <i>Gynecology and Minimally Invasive Therapy</i> , 2017, 6, 108-112.	0.2	0
75	The anti-cancer effects of itraconazole in epithelial ovarian cancer. <i>Scientific Reports</i> , 2017, 7, 6552.	1.6	37
76	Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e22.	1.0	38
77	Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 170.	0.6	33
78	Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e12.	1.0	54
79	Laparoendoscopic single-site radical hysterectomy for early stage cervical cancer. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 110.	0.6	3
80	Extrauterine epithelioid trophoblastic tumor in hysterectomized woman. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 124.	0.6	18
81	Catamenial hemoptysis accompanied by subcutaneous endometriosis treated with combination therapy. <i>Obstetrics and Gynecology Science</i> , 2017, 60, 236.	0.6	2
82	Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. <i>Radiation Oncology Journal</i> , 2017, 35, 39-47.	0.7	28
83	Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 595-606.	1.3	24
84	Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 635-642.	1.3	10
85	Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. <i>Cancer Research and Treatment</i> , 2017, 49, 915-926.	1.3	58
86	Development and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K). <i>Journal of Korean Medical Science</i> , 2016, 31, 1969.	1.1	4
87	Preventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology Guideline. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e30.	1.0	9
88	Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 5729-5742.	3.3	35
89	Time-lapse imaging of sentinel lymph node using indocyanine green with near-infrared fluorescence imaging in early endometrial cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e27.	1.0	11
90	Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e46.	1.0	9

#	ARTICLE	IF	CITATIONS
91	Retroperitoneal Approach in Single-Port Laparoscopic Hysterectomy. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2016, 20, e2016.00001.	0.5	4
92	Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e20.	1.0	17
93	Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e24.	1.0	6
94	Prognostic significance of annexin A2 and annexin A4 expression in patients with cervical cancer. <i>BMC Cancer</i> , 2016, 16, 448.	1.1	26
95	Primary malignant melanoma of cervix and vagina. <i>Obstetrics and Gynecology Science</i> , 2016, 59, 415.	0.6	12
96	In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy. <i>Scientific Reports</i> , 2016, 6, 38348.	1.6	55
97	The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis. <i>Scientific Reports</i> , 2016, 6, 39334.	1.6	30
98	c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. <i>Scientific Reports</i> , 2016, 6, 38502.	1.6	34
99	Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. <i>Gynecologic Oncology</i> , 2016, 143, 252-257.	0.6	20
100	Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2016, 56, 639-647.	0.4	14
101	Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 618-627.	1.9	27
102	Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma. <i>European Radiology</i> , 2016, 26, 4148-4154.	2.3	15
103	Women with double primary cancers of the colorectum and endometrium: do they have Lynch syndrome?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 199, 208-212.	0.5	4
104	Clinical outcomes of primary surgical treatment for acquired vulvar lymphangioma circumscriptum. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 157-162.	0.8	18
105	Uterine Fibroids: Correlation of T2 Signal Intensity with Semiquantitative Perfusion MR Parameters in Patients Screened for MR-guided High-Intensity Focused Ultrasound Ablation. <i>Radiology</i> , 2016, 278, 925-935.	3.6	17
106	Dynamins 2 Inhibitors as Novel Therapeutic Agents Against Cervical Cancer Cells. <i>Anticancer Research</i> , 2016, 36, 6381-6388.	0.5	13
107	Prognostic model for disease-free survival, lymphatic and/or hematogenous recurrence, in patients with early stage cervical cancer treated with radical hysterectomy: A Korean Gynecologic Oncology Group Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e17000-e17000.	0.8	0
108	Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer. <i>International Journal of Cancer</i> , 2015, 137, 221-229.	2.3	39

#	ARTICLE	IF	CITATIONS
109	Robotic high para-aortic lymph node dissection with high port placement using same port for pelvic surgery in gynecologic cancer patients. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 222.	1.0	2
110	Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification. <i>Obstetrics and Gynecology Science</i> , 2015, 58, 124.	0.6	45
111	Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. <i>Oncotarget</i> , 2015, 6, 35040-35050.	0.8	48
112	Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. <i>Oncotarget</i> , 2015, 6, 26746-26756.	0.8	55
113	The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 190, 26-30.	0.5	5
114	Borderline ovarian tumor in women aged ≥ 65 years: impact on recurrence and survival. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 184, 38-42.	0.5	11
115	A prospective comparative study of cosmetic satisfaction for three different surgical approaches. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015, 190, 48-51.	0.5	6
116	Robotic Single-port Hysterectomy, Adnexectomy, and Lymphadenectomy in Endometrial Cancer. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 322.	0.3	24
117	Is laparoendoscopic single-site surgery (LESS) retroperitoneal hysterectomy feasible?: Surgical outcomes of the initial 27 cases. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2015, 54, 150-154.	0.5	4
118	Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer. <i>Carcinogenesis</i> , 2015, 36, bgv140.	1.3	27
119	HER2 as a novel therapeutic target for cervical cancer. <i>Oncotarget</i> , 2015, 6, 36219-36230.	0.8	51
120	Mesothelial cell inclusions in pelvic and para-aortic lymph nodes: a clinicopathologic analysis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5318-26.	0.5	3
121	Analysis of clinical outcomes of patients with adenoid cystic carcinoma of Bartholin glands. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5688-94.	0.5	10
122	Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 28.	0.6	27
123	Primary ovarian choriocarcinoma mimicking ectopic pregnancy. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 330.	0.6	19
124	Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 108-117.	0.6	29
125	Postoperative outcomes of MR-invisible stage IB1 cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 168.e1-168.e7.	0.7	16
126	Laparoendoscopic single-site (LESS) myomectomy: characteristics of the appropriate myoma. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 175, 58-61.	0.5	15

#	ARTICLE	IF	CITATIONS
127	Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2014, 53, 343-347.	0.5	19
128	Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: A multicenter review of 114 cases. <i>Gynecologic Oncology</i> , 2014, 132, 70-75.	0.6	63
129	Surgical Outcomes of a New Approach to Laparoscopic Myomectomy: Single-Port and Modified Suture Technique. <i>Journal of Minimally Invasive Gynecology</i> , 2014, 21, 580-585.	0.3	31
130	Aggressive angiomyxoma of the vulva: A case report. <i>Obstetrics and Gynecology Science</i> , 2014, 57, 164.	0.6	9
131	Vaginal cancer with multiple liver and pulmonary metastases that achieved long-term survival. <i>Obstetrics and Gynecology Science</i> , 2013, 56, 416.	0.6	1
132	Reply to JY Hwang. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 97.	1.0	0
133	The effect of surgical wound on ovarian carcinoma growth in an animal model. <i>Anticancer Research</i> , 2013, 33, 3177-84.	0.5	5
134	A rare case of primary ovarian leiomyoma with atypical Meigs' syndrome. <i>Korean Journal of Obstetrics & Gynecology</i> , 2012, 55, 285.	0.1	1
135	Superior vena cava syndrome secondary to hickman catheter in the advanced cervical cancer patient treated with concurrent chemoradiotherapy: A case report. <i>Korean Journal of Obstetrics & Gynecology</i> , 2012, 55, 761.	0.1	0
136	A case of primitive neuroectodermal tumor of the ovary. <i>Korean Journal of Obstetrics & Gynecology</i> , 2012, 55, 777.	0.1	1
137	Primary signet ring cell carcinoma of the uterine cervix: A case report. <i>Korean Journal of Obstetrics & Gynecology</i> , 2011, 54, 570.	0.1	5
138	The expression of the miRNA-200 family in endometrial endometrioid carcinoma. <i>Gynecologic Oncology</i> , 2011, 120, 56-62.	0.6	116
139	Video-assisted thoracoscopic surgery for pulmonary metastasis of gestational trophoblastic neoplasia. <i>Korean Journal of Obstetrics and Gynecology</i> , 2010, 53, 1024.	0.1	0
140	The prognostic significance of the SUVmax (maximum standardized uptake value for F-18) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 Td results. <i>Gynecologic Oncology</i> , 2009, 115, 65-68.	0.6	78
141	Altered MicroRNA Expression in Cervical Carcinomas. <i>Clinical Cancer Research</i> , 2008, 14, 2535-2542.	3.2	293
142	Increased toll-like receptor 9 expression in cervical neoplasia. <i>Molecular Carcinogenesis</i> , 2007, 46, 941-947.	1.3	74
143	Decreased galectin-3 expression during the progression of cervical neoplasia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 241-247.	1.2	36
144	Selected Adnexal Cystic Masses in Postmenopausal Women Can be Safely Managed by Laparoscopy. <i>Journal of Korean Medical Science</i> , 2005, 20, 468.	1.1	10

#	ARTICLE	IF	CITATIONS
145	Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Human Pathology, 2005, 36, 626-633.	1.1	59
146	eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Human Pathology, 2005, 36, 1197-1203.	1.1	34